Citations

Showing 10 of 108081 citations.

Randomized controlled trials in mild cognitive impairment
Petersen, Ronald C. , Thomas, Ronald G. , Aisen, Paul, Mohs, Richard C. , Carrillo, María C. , Albert, Marilyn S.

Mayo Clinic

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1751-1758

10.1212/wnl.0000000000003907 | PMID 28381516 Get It

A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Jack, Clifford R., Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Sadowski, Martin, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Hsiung, Robin, Schultz, Susan, Burns, Jeffrey, Jicha, Gregory, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R. , Hsiung, Ging‐Yuek Robin , Jicha, Gregory A. , Sadowski, Martin , van Dyck, Christopher H, Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Schultz, Susan, Burns, Jeffrey, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1768-1775

10.1212/wnl.0000000000003904 | PMID 28381506 Get It

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheum
Rider, Lisa G. , Ruperto, Nicolino , Bayat, Nastaran, Amato, Anthony A. , Dastmalchi, Maryam, Katz, James D. , Mammen, Andrew L. , Visser, Marianne de, Ytterberg, Steven R. , Lundberg, Ingrid E. , Chung, Lorinda, Dankó, Katalin , Torre, Ignacio García‐De La , Villa, Luca, Rinaldi, Mariangela, Rockette, Howard E., Lachenbruch, Peter A., Miller, Frederick W. , Vencovský, Jiří , Rouster‐Stevens, Kelly , Huber, Adam M. , Selva-O’Callaghan, Albert , Rutkove, Seward B. , Dimachkie, Mazen M. , Olesińska, Marzena , Chung, Leland W.K. , Shinjo, Samuel Katsuyuki , Ramchandren, Sindhu , Saketkoo, Lesley Ann , Mann, H. , Aggarwal, Rohit , Erman, Brian , Feldman, Brian Michael , Oddis, Chester V. , Chinoy, Hector , Cooper, Robert G. , Fiorentino, David Franklin , Isenberg, David , Visser, Marianne de, Chung, Lorinda, Song, Yeong Wook , Mann, Heřman , Vencovsky, Jiri , Shinjo, Samuel Katsuyuki , Selva O'Callaghan, Albert , Chung, Lorinda , García-De La Torre, Ignacio , Dimachkie, Mazen M , Lundberg, Ingrid E , Pistorio, Angela

Mayo Clinic

Arthritis & Rheumatology | April 6, 2017 | Volume: 69 | Issue: 5 | Pages: 898-910

10.1002/art.40064 | PMID 28382787 Get It

ObjectiveTo develop response criteria for adult dermatomyositis (DM) and polymyositis (PM).MethodsExpert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus.ResultsConsensus was reached for a conjoint analysis–based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0–100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (P < 0.001).ConclusionThe response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute percent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
Regional assessment of in vivo myocardial stiffness using 3D magnetic resonance elastography in a porcine model of myocardial infarction
Arunachalam, Shivaram P. , Arani, Arvin , Baffour, Francis , Rysavý, J, Rossman, Phillip J. , Glaser, Kevin J. , Lake, David S. , Trzasko, Joshua D. , McGee, Kiaran P. , Araoz, Philip A. , Rysavy, Joseph A, Manduca, Armando , Ehman, Richard L. , Arunachalam, S P , Arani, Arvin , Baffour, Francis I

Mayo Clinic

Magnetic Resonance in Medicine | April 6, 2017 | Volume: 79 | Issue: 1 | Pages: 361-369

10.1002/mrm.26695 | PMID 28382658 Get It

Purpose The stiffness of a myocardial infarct affects the left ventricular pump function and remodeling. Magnetic resonance elastography (MRE) is a noninvasive imaging technique for measuring soft‐tissue stiffness in vivo. The purpose of this study was to investigate the feasibility of assessing in vivo regional myocardial stiffness with high‐frequency 3D cardiac MRE in a porcine model of myocardial infarction, and compare the results with ex vivo uniaxial tensile testing. Methods Myocardial infarct was induced in a porcine model by embolizing the left circumflex artery. Fourteen days postinfarction, MRE imaging was performed in diastole using an echocardiogram‐gated spin‐echo echo‐planar‐imaging sequence with 140‐Hz vibrations and 3D MRE processing. The MRE stiffness and tensile modulus from uniaxial testing were compared between the remote and infarcted myocardium. Results Myocardial infarcts showed increased in vivo MRE stiffness compared with remote myocardium (4.6 ± 0.7 kPa versus 3.0 ± 0.6 kPa, P = 0.02) within the same pig. Ex vivo uniaxial mechanical testing confirmed the in vivo MRE results, showing that myocardial infarcts were stiffer than remote myocardium (650 ± 80 kPa versus 110 ± 20 kPa, P = 0.01). Conclusions These results demonstrate the feasibility of assessing in vivo regional myocardial stiffness with high‐frequency 3D cardiac MRE. Magn Reson Med 79:361–369, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia
Kittah, Nana Esi, Vella, Adrian

Mayo Clinic

European Journal of Endocrinology | April 6, 2017 | Volume: 177 | Issue: 1 | Pages: R37-R47

10.1530/eje-16-1062 | PMID 28381450 Get It

Glucose is the main substrate utilized by the brain and as such multiple regulatory mechanisms exist to maintain glucose concentrations. When these mechanisms fail or are defective, hypoglycemia ensues. Due to these robust mechanisms, hypoglycemia is uncommon and usually occurs in the setting of the treatment of diabetes using glucose-lowering agents such as sulfonylureas or insulin. The symptoms of hypoglycemia are non-specific and as such it is important to confirm hypoglycemia by establishing the presence of Whipple’s triad before embarking on an evaluation for hypoglycemia. When possible, evaluation of hypoglycemia should be carried out at the time of spontaneous occurrence of symptoms. If this is not possible then one would want to create the circumstances under which symptoms occur. In cases where symptoms occur in the post absorptive state, a 72-h fast should be performed. Likewise, if symptoms occur after a meal then a mixed meal study may be the test of choice. The causes of endogenous hyperinsulinemic hypoglycemia include insulinoma, post-bariatric hypoglycemia and noninsulinoma pancreatogenous hypoglycemia syndrome. Autoimmune hypoglycemia syndrome is clinically and biochemically similar to insulinoma but associated with high levels of insulin antibodies and plasma insulin. Other important causes of hypoglycemia include medications, non-islet cell tumors, hormonal deficiencies, critical illness and factitious hypoglycemia. We provide an overview of the pathogenesis and management of hypoglycemia in these situations.
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Czuczman, Myron S., Trněný, Marek , Davies, Andrew , Rule, Simon , Linton, Kim , Wagner‐Johnston, Nina D. , Gascoyne, Randy D. , Slack, Graham W. , Eberhard, David A., Hernandez‐Ilizaliturri, Francisco J. , Salles, Gilles , Zinzani, Pier Luigi , Wright, George W. , Staudt, Louis M. , Yang, Yandan , Lih, Chih-Jian, Russo, Jacqueline, Thakurta, Anjan , Hagner, Patrick R. , Fustier, Pierre , Song, Dale, Lewis, Ian D., Brousset, Pierre , Witzig, Thomas E. , Williams, P. Mickey , Lih, Chih‐Jian, Zinzani, Pier Luigi , Salles, Gilles A , Davies, Andrew , Trnĕný, Marek , Linton, Kim M , Wright, George

Mayo Clinic

Clinical Cancer Research | April 5, 2017 | Volume: 23 | Issue: 15 | Pages: 4127-4137

10.1158/1078-0432.ccr-16-2818 | PMID 28381416 Get It

Abstract Purpose: Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Experimental Design: Patients with DLBCL who received ≥2 prior therapies were stratified by DLBCL subtype [germinal center B-cell (GCB) vs. non-GCB; determined by immunohistochemistry (IHC)] and then randomized 1:1 to lenalidomide (25 mg/day, 21 days of 28-day cycle) or IC (gemcitabine, rituximab, etoposide, or oxaliplatin). Crossover to lenalidomide was permitted for IC-treated patients with radiologically confirmed progressive disease. The primary endpoint was overall response rate (ORR). Progression-free survival (PFS), overall survival, and subtype analysis [GCB vs. activated B-cell (ABC)] using gene expression profiling (GEP) were exploratory endpoints. Results: Stage 1: 102 DLBCL patients (by IHC: non-GCB, n = 54; GCB, n = 48) received ≥1 dose of lenalidomide or IC. Hematologic treatment-emergent adverse events with lenalidomide versus IC included neutropenia (42.6%; 36.4%), anemia (33.3%; 47.3%), thrombocytopenia (24.1%; 43.6%), and leukopenia (5.6%; 12.7%), respectively. Overall, lenalidomide-treated patients had an ORR of 27.5% versus 11.8% in IC (ORRs were similar regardless of IHC-defined DLBCL subtype). Median PFS was increased in patients receiving lenalidomide (13.6 weeks) versus IC (7.9 weeks; P = 0.041), with greater improvements in non-GCB patients (15.1 vs. 7.1 weeks, respectively; P = 0.021) compared with GCB (10.1 vs. 9.0 weeks, respectively; P = 0.550). Conclusions: The clinical benefit of lenalidomide monotherapy in DLBCL patients was more evident in the non-GCB subtype. Exploratory analyses suggest that this preferential benefit was more pronounced in the GEP-defined ABC population, demonstrating a need for additional studies of lenalidomide in DLBCL using GEP subtyping. Clin Cancer Res; 23(15); 4127–37. ©2017 AACR.
Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction
Obokata, Masaru , Reddy, Yogesh N.V. , Pislaru, Sorin V. , Melenovský, Vojtěch , Borlaug, Barry A. , Sabbah, Michael S. , Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru , Melenovský, Vojtěch

Mayo Clinic

Circulation | April 5, 2017 | Volume: 136 | Issue: 1 | Pages: 6-19

10.1161/circulationaha.116.026807 | PMID 28381470 Get It

Background: Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome. Phenotyping patients into pathophysiologically homogeneous groups may enable better targeting of treatment. Obesity is common in HFpEF and has many cardiovascular effects, suggesting that it may be a viable candidate for phenotyping. We compared cardiovascular structure, function, and reserve capacity in subjects with obese HFpEF, those with nonobese HFpEF, and control subjects. Methods: Subjects with obese HFpEF (body mass index ≥35 kg/m 2 ; n=99), nonobese HFpEF (body mass index <30 kg/m 2 ; n=96), and nonobese control subjects free of HF (n=71) underwent detailed clinical assessment, echocardiography, and invasive hemodynamic exercise testing. Results: Compared with both subjects with nonobese HFpEF and control subjects, subjects with obese HFpEF displayed increased plasma volume (3907 mL [3563–4333 mL] versus 2772 mL [2555–3133 mL], and 2680 mL [2380–3006 mL]; P <0.0001), more concentric left ventricular remodeling, greater right ventricular dilatation (base, 34±7 versus 31±6 and 30±6 mm, P =0.0005; length, 66±7 versus 61±7 and 61±7 mm, P <0.0001), more right ventricular dysfunction, increased epicardial fat thickness (10±2 versus 7±2 and 6±2 mm; P <0.0001), and greater total epicardial heart volume (945 mL [831–1105 mL] versus 797 mL [643–979 mL] and 632 mL [517–768 mL]; P <0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels. Pulmonary capillary wedge pressure was correlated with body mass and plasma volume in obese HFpEF ( r =0.22 and 0.27, both P <0.05) but not in nonobese HFpEF ( P ≥0.3). The increase in heart volumes in obese HFpEF was associated with greater pericardial restraint and heightened ventricular interdependence, reflected by increased ratio of right- to left-sided heart filling pressures (0.64±0.17 versus 0.56±0.19 and 0.53±0.20; P =0.0004), higher pulmonary venous pressure relative to left ventricular transmural pressure, and greater left ventricular eccentricity index (1.10±0.19 versus 0.99±0.06 and 0.97±0.12; P <0.0001). Interdependence was enhanced as pulmonary artery pressure load increased ( P for interaction <0.05). Compared with those with nonobese HFpEF and control subjects, obese patients with HFpEF displayed worse exercise capacity (peak oxygen consumption, 7.7±2.3 versus 10.0±3.4 and12.9±4.0 mL/min·kg; P <0.0001), higher biventricular filling pressures with exercise, and depressed pulmonary artery vasodilator reserve. Conclusions: Obesity-related HFpEF is a genuine form of cardiac failure and a clinically relevant phenotype that may require specific treatments.
Potential Cost Savings of Contrast-Enhanced Digital Mammography
Patel, Bhavika , Gray, Richard J. , Pockaj, Barbara A. , Patel, Bhavika K

Mayo Clinic

American Journal of Roentgenology | April 5, 2017 | Volume: 208 | Issue: 6 | Pages: W231-W237

10.2214/ajr.16.17239 | PMID 28379734 Get It

Endoscopic Skipping of the Terminal Ileum in Pediatric Crohn Disease
Mansuri, Ishrat , Bruining, David H. , Kolbe, Amy B. , Fidler, Jeff L. , Samuel, Sunil, Tung, Jeanne , Fletcher, Joel G. , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | April 5, 2017 | Volume: 208 | Issue: 6 | Pages: W216-W224

10.2214/ajr.16.16575 | PMID 28379745 Get It

Comprehensive-Integrated Postacute Outpatient Brain Injury Rehabilitation
Malec, James F. , Schafer, David J., Jacket, Mary

Mayo Clinic

NeuroRehabilitation | April 5, 2017 | Volume: 2 | Issue: 3 | Pages: 1-11

10.3233/nre-1992-2303 Get It